Anison’s core technology specifically targets the root cause of HPV, a first in the treatment landscape for HPV-associated diseases. Unlike current treatments that only address symptoms, our innovative solution directly impacts HPV-infected cells by degrading viral proteins, halting disease progression at its source.

Absolutely. Anison’s product is a topical formulation, meaning it can be applied directly to the affected area without the need for surgery or other invasive procedures. This approach not only improves patient comfort but also reduces potential side effects associated with more aggressive treatment options.

Anison’s therapy is designed to go beyond symptom management by targeting the viral proteins (E6 and E7) that drive HPV’s harmful effects, potentially halting disease progression. Preclinical studies have demonstrated that Anison’s compounds can reduce viral protein levels and prevent lesion recurrence in HPV-positive animal models, indicating the potential for long-lasting and effective relief compared to conventional symptom-targeted treatments.

The need for HPV-specific treatments is vast, with HPV affecting millions worldwide. Despite the availability of vaccines, there is still no treatment specifically targeting HPV-infected cells, leaving many with limited options that only address symptoms. Given the long-term risks of HPV, including its link to precancerous lesions and cancers, an effective therapy that targets HPV itself would address a significant unmet need and could capture a large share of the HPV-associated disease market, valued at over $26 billion.

Anison is currently at the preclinical stage, with plans to complete this phase by 2025. Following successful preclinical studies, Anison aims to enter clinical trials and, depending on regulatory pathways and trial outcomes, could bring the therapy to market in the next few years. Investor support is crucial at this stage to help accelerate development and meet clinical milestones.

Current treatments for HPV-associated diseases primarily focus on symptom management, targeting only the visible effects, such as genital warts, rather than eliminating the underlying infection. These methods often involve invasive procedures like surgery or cryotherapy, which can be painful, may cause scarring, and have high recurrence rates. Additionally, there is no FDA-approved treatment specifically targeting the root cause of HPV infections.

Anison’s therapy addresses these gaps by directly targeting HPV-infected cells through a non-invasive, topical approach. By degrading HPV’s key oncoproteins, E6 and E7, Anison’s therapy tackles the virus at its source, potentially preventing disease progression to more severe conditions, including cancer. This innovative approach offers a safer, more effective solution, reducing recurrence rates and minimizing the need for invasive procedures.

While HPV vaccines are effective at preventing new infections, they do not address existing HPV infections or the millions already affected by HPV-associated diseases. Vaccination uptake has been slow and primarily targets younger individuals, leaving adults and those already infected without specific treatment options. Additionally, there are over 200 subtypes of HPV, with vaccines covering only a fraction of these.

Anison’s therapy is designed to target and treat active HPV infections directly, especially for those who have developed precancerous lesions or genital warts due to HPV. By focusing on degrading HPV’s core proteins, Anison’s therapy can potentially halt disease progression and provide relief for individuals who cannot benefit from the vaccine. This treatment approach complements vaccination efforts, offering a solution for those who need immediate intervention